Why ImmunityBio, Inc. (IBRX) Stock Rose 10.5% on Oct 27, 2026
The clearest new catalyst: ANKTIVA® Plus BCG trial database lock.
Why did IBRX stock rise?
ImmunityBio rose 10.5% on October 27, 2026, driven by the company's announcement of a database lock for its registrational trial of ANKTIVA® Plus BCG in BCG-naïve non-muscle invasive bladder cancer. The published narrative citing a stake reduction by Davidson Kahn Capital Management does not align with the confirmed session move or the primary catalyst evident in the candidate sources.
- ANKTIVA® Plus BCG trial database lock: ImmunityBio announced a database lock for its registrational trial of the locally delivered, chemotherapy-free ANKTIVA® Plus BCG combination in BCG-naïve non-muscle invasive bladder cancer, a key milestone toward potential regulatory approval.
Initial detection
BestStocks first flagged IBRX intraday on Oct 27, 2026; this analysis was finalized after the close using the confirmed +10.5% session move and additional catalyst research.
Show the initial intraday note
ImmunityBio gained 7.57% to $8.40 after Davidson Kahn Capital Management LLC trimmed its stake in the company, according to defenseworld.net. Volume stands at 3.3M shares (0.82x normal for this time of day), suggesting modest participation behind the move.
What to watch next: IBRX earnings release scheduled for November 3, 2026 (consensus EPS estimate: –$0.07); confirm the exact time and any guidance revisions.
Other developments that session
Davidson Kahn Capital Management reduced IBRX stake by 50.9%, selling 83,092 shares in Q3.
Frequently asked questions
Why did ImmunityBio, Inc. (IBRX) stock rise on Oct 27, 2026?
ImmunityBio rose 10.5% on October 27, 2026, driven by the company's announcement of a database lock for its registrational trial of ANKTIVA® Plus BCG in BCG-naïve non-muscle invasive bladder cancer. The published narrative citing a stake reduction by Davidson Kahn Capital Management does not align with the confirmed session move or the primary catalyst evident in the candidate sources.
How much did IBRX stock rise on Oct 27, 2026?
IBRX rose 10.5% during the Oct 27, 2026 trading session.
What were the main drivers behind IBRX's move?
ANKTIVA® Plus BCG trial database lock.